Macrocyclic inhibitors of flaviviridae viruses

Provided are compounds of Formula (I) and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. In one embodiment the compound is (E)-(1S,13R,14R,17S,...

Full description

Saved in:
Bibliographic Details
Main Authors SANVOISIN JONATHAN, WATT GREGORY M, FLIRI HANS G, LAZARIDES LINOS, KEATS ANDREW J, MACKMAN RICHARD L, APPLEBY TODD, PETTIT SIMON N, STEADMAN VICTORIA A, POULLENNEC KARINE G
Format Patent
LanguageEnglish
Published 31.07.2015
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided are compounds of Formula (I) and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. In one embodiment the compound is (E)-(1S,13R,14R,17S,20S)-20-(3-Hydroxy-benzyl)-17-isopropyl-13-methoxy-14-methyl-3-oxa-6-thia-16,19,22,26-tetraazatricyclo[20.3.1.1*5,8*]heptacosa-5(27),7,9-triene-2,15,18,21-tetraone
Bibliography:Application Number: NZ20110612159